Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung
A phase 2 trial of Encorafenib, Binimetinib in non-small-cell lung cancer and small-cell lung cancer, run by Pierre Fabre Medicament, active and no longer recruiting.
Overview
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05195632 by Pierre Fabre Medicament, with 63 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2024-05-27. Interventions recorded: Encorafenib, Binimetinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Shares Binimetinib, Encorafenib.
- TrialA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Shares Binimetinib, Encorafenib.
- TrialCOLUMBUS
Shares Binimetinib, Encorafenib.
- PairingBRAF inhibitor + MEK inhibitor
Shares Encorafenib, Non-small-cell lung cancer.
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Encorafenib, Non-small-cell lung cancer.
- CompanyPierre Fabre
Shares Binimetinib, Encorafenib.
- PathwayMelanoma (KEGG map)
Shares Binimetinib, Encorafenib.
- Treatmenttherascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)
Shares Encorafenib, Non-small-cell lung cancer.